Home › Merck Provides Update on Next Steps for TREDAPTIVE (extended-release niacin/laropiprant)
 

Keywords :   


Merck Provides Update on Next Steps for TREDAPTIVE (extended-release niacin/laropiprant)

2013-01-11 13:39:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE (extended-release niacin/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Language:  English Contact HTML:  MerckMedia:Pamela Eisele, 908-423-5042orSkip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: update steps merck extendedrelease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Forecast Discussion Number 5
06.10Hurricane Kirk Graphics
06.10Tropical Storm Milton Wind Speed Probabilities Number 5
06.10Tropical Storm Milton Public Advisory Number 5
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Hurricane Kirk Forecast Discussion Number 29
06.10Hurricane Kirk Wind Speed Probabilities Number 29
More »